An S&P 500 COVID vaccine stock is up 600% this year

Article

In brief
A vaccine maker, not an AI stock, leads the S&P 500 in 2026
A breakthrough in a cancer vaccine trial and Nasdaq-100 inclusion fueled the rally.
Full trial results are due on October 24. The figures are still unknown.
Read the original story, “An S&P 500 COVID vaccine stock is up 600% this year,” by Lockridge Okoth on no.beincrypto.com

Disclaimer: Includes third-party opinions. No advice. Binance AI may be used without guarantee. See T&Cs.